AR066334A1 - Uso de un antagonista del receptor y5 del neuropeptido y (npy) - Google Patents
Uso de un antagonista del receptor y5 del neuropeptido y (npy)Info
- Publication number
- AR066334A1 AR066334A1 ARP080101797A ARP080101797A AR066334A1 AR 066334 A1 AR066334 A1 AR 066334A1 AR P080101797 A ARP080101797 A AR P080101797A AR P080101797 A ARP080101797 A AR P080101797A AR 066334 A1 AR066334 A1 AR 066334A1
- Authority
- AR
- Argentina
- Prior art keywords
- npy
- neuropeptide
- subject
- receptor antagonist
- antagonist
- Prior art date
Links
- 101710151321 Melanostatin Proteins 0.000 title 1
- 102100028427 Pro-neuropeptide Y Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000002464 receptor antagonist Substances 0.000 abstract 2
- 229940044551 receptor antagonist Drugs 0.000 abstract 2
- 208000014311 Cushing syndrome Diseases 0.000 abstract 1
- 208000037171 Hypercorticoidism Diseases 0.000 abstract 1
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 abstract 1
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 abstract 1
- 102000028582 Neuropeptide Y5 receptor Human genes 0.000 abstract 1
- 108010046593 Neuropeptide Y5 receptor Proteins 0.000 abstract 1
- 102000003797 Neuropeptides Human genes 0.000 abstract 1
- 108090000189 Neuropeptides Proteins 0.000 abstract 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/301—Anxiety or phobic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/303—Eating disorders, e.g. anorexia, bulimia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Antagonista del receptor Y5 del neuropéptido Y (NPY). Reivindicacion 1: El uso de un antagonista del receptor Y5 del NPY (neuropéptido Y) en la manufactura de un medicamento para el tratamiento de un trastorno relacionado con el hipercortisolismoen un sujeto, donde dicho sujeto se caracteriza por presentar un nivel de cortisol mayor que aproximadamente 125 nmol/l después de un ensayo de provocacion sobre la base de dexametasona del eje HPA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91623207P | 2007-05-04 | 2007-05-04 | |
| US95042107P | 2007-07-18 | 2007-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066334A1 true AR066334A1 (es) | 2009-08-12 |
Family
ID=39943883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101797A AR066334A1 (es) | 2007-05-04 | 2008-04-28 | Uso de un antagonista del receptor y5 del neuropeptido y (npy) |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR066334A1 (es) |
| CL (1) | CL2008001296A1 (es) |
| WO (1) | WO2008137270A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013135769A1 (en) * | 2012-03-13 | 2013-09-19 | Abbvie Inc. | Method for selecting or identifying a subject for v1b antagonist therapy |
| EP2917202B1 (en) * | 2012-11-07 | 2018-05-02 | Karus Therapeutics Limited | Novel histone deacetylase inhibitors and their use in therapy |
| CA2911856A1 (en) | 2013-05-10 | 2014-11-13 | Karus Therapeutics Ltd | Tri-substituted amino hydroxamate compounds and pharmaceutical compositions thereof for use as histone deacetylase inhibitors |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602024A (en) * | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| KR100895662B1 (ko) * | 2001-03-23 | 2009-05-07 | 코어셉트 쎄라퓨틱스, 잉크. | 글루코코르티코이드 수용체 특이적 길항제를 이용한스트레스 장애의 치료 방법 |
| JP2006526635A (ja) * | 2003-06-02 | 2006-11-24 | サマリタン，ファーマスーティカルス，インク． | 血清中コルチゾール量を調節する方法および組成物 |
-
2008
- 2008-04-17 WO PCT/US2008/060549 patent/WO2008137270A1/en not_active Ceased
- 2008-04-28 AR ARP080101797A patent/AR066334A1/es unknown
- 2008-05-05 CL CL2008001296A patent/CL2008001296A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008137270A1 (en) | 2008-11-13 |
| CL2008001296A1 (es) | 2009-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6541613A2 (es) | Combinaciones de un antagonista de los receptores muscarínicos y un agonista del adreno-receptor beta 2 | |
| HN2009000997A (es) | Antagonistas del receptor de progesterona | |
| MX2021011728A (es) | Agonista beta adrenergico y metodos de uso de este. | |
| AR066334A1 (es) | Uso de un antagonista del receptor y5 del neuropeptido y (npy) | |
| NI201100068A (es) | Combinación de una insulina y un agonista de glp-1. | |
| CO6351776A2 (es) | Derivados de ciclohexil-amida y su uso como antagonistas de los receptores de crf-1 | |
| CL2008001498A1 (es) | Uso de un anticuerpo contra el factor d en la prevencion o tratamiento de una condicion ocular asociada al complemento. | |
| CR20110421A (es) | Agonistas y antagonistas del receptor de s1p, y métodos de uso de los mismos | |
| CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
| CL2009000545A1 (es) | Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer. | |
| CL2012000702A1 (es) | Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson. | |
| CL2010001483A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune. | |
| CL2008000418A1 (es) | Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica. | |
| UY32225A (es) | Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2 | |
| CL2009000532A1 (es) | Compuestos derivados de piridin-2-ilo; agonista del receptor s1p1/edg1; composición farmacéutica que los comprende; uso en trastornos asociados con el sitema inmunitario. | |
| CL2011003085A1 (es) | Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes. | |
| AR084459A1 (es) | Analogos de glucagon que presentan actividad de receptor de gip | |
| CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
| AR084122A1 (es) | COMBINACIONES FARMACEUTICAS, DE UN AGONISTA DE RECEPTOR b-3 ADRENERGICO Y UN ANTAGONISTA DE RECEPTOR MUSCARINICO | |
| CL2008003266A1 (es) | Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales. | |
| CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
| CL2014000250A1 (es) | Procedimiento para el refuerzo de una unidad de construccion, incluyendo la etapa de encolado de un tejido textil sobre la superficie de la unidad de construccion por medio de un adhesivo, donde el tejido textil presenta una ductilidad >=1,0 antes del encolado, el adhesivo presenta una ductilidad >= 1,5 en estado de endurecimiento y la unidad de construccion posee una ductilidad >=2 despues del encolado; unidad de construccion; uso. | |
| MX2020004166A (es) | Seccion de escotilla para un dispositivo electronico de suministro de aerosol. | |
| MX382823B (es) | Antagonistas a2a como mejoradores de la función cognitiva y motora | |
| AR072639A1 (es) | Pirazinonas como moduladores de la actividad del receptor del factor liberador de corticotropina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |